Support Centre
24 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
DOI 10.1186/ISRCTN74348595
ClinicalTrials.gov identifier
EudraCT number
Public title Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
Scientific title
Acronym SEARCH
Serial number at source CTSU SEARCH1
Study hypothesis Do larger reductions in blood cholesterol produce larger, and worthwhile, reductions in cardiovascular risk, and does homocysteine-lowering with folic acid and vitamin B12 reduce cardiovascular risk?
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Coronary heart disease
Participants - inclusion criteria Men and women who have survivied a heart attack and in whom statin therapy is indicated.
Participants - exclusion criteria Age under 18 years or over 80 at invitation, contraindications to either study drug, other predominant medical problem.
Anticipated start date 30/07/1998
Anticipated end date 31/12/2007
Status of trial Completed
Patient information material
Target number of participants 12,064
Interventions Simvastatin 80 mg versus 20 mg daily, and separately folic acid 2 mg plus 1 mg vitamin B12 daily or matching placebo tablets.
Primary outcome measure(s) Major vascular events (MVEs) during the scheduled treatment period
Secondary outcome measure(s) MVEs separately during the first year and in the later years of the study, MVEs in patients subdivided by pre-randomisation lipid levels, MVEs in the presence and absence of the other randomised treatments, major coronary events, total strokes
Sources of funding A grant to Oxford University from Merck and Co.
Trial website
Publications 1. 2008 results in http://www.ncbi.nlm.nih.gov/pubmed/18650507
2. 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/20571015
Contact name Prof  Rory  Collins
  Address Clinical Trial Service Unit
Richard Doll Building
Old Road Campus
  City/town Oxford
  Zip/Postcode OX3 7LF
  Country United Kingdom
  Tel +44 (0)1865 743743
  Fax +44 (0)1865 743985
  Email Secretary@ctsu.ox.ac.uk
Sponsor University of Oxford (UK)
  Address University Offices
Wellington Square
  City/town Oxford
  Zip/Postcode OX1 2JD
  Country United Kingdom
  Tel +44 (0)1865 270000
  Fax +44 (0)1865 270708
  Email search@ctsu.ox.ac.uk
  Sponsor website: http://www.ox.ac.uk
Date applied 15/08/2005
Last edited 24/06/2010
Date ISRCTN assigned 09/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.